Biologic R&D Cash Outlays Exceed Those For Small Molecules – Tufts Study

Companies' out-of-pocket expenses to bring a biopharmaceutical to market exceed those for new chemical entities, a Tufts Center for the Study of Drug Development analysis found

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet